ARTICLE | Clinical News
MX6: Began Phase II trial
April 24, 2000 7:00 AM UTC
Maxia Pharmaceuticals Inc., San Diego, Calif. Product: MX6 Business: Cancer Therapeutic category: Apoptosis Target: Retinoic acid receptor (RAR) gamma Description: Topical small molecule inducer of a...